Skip to Content

Tag: Tirzepatide

Also Noted

New weight loss drug reduces AHI in certain patients

April 17, 2024HME News Staff

INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events...

Sleep Apnea, Tirzepatide, weight loss drugs

Read Full Articlered right arrow icon